logo

For the Inventor, By the Inventor

Wissous, France

Jonathan Reid Frost

This inventor holds 23 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Synthelabo, Mitsubishi Pharma Corporation, Sanofi-Aventis. Active years: 1981-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Reid Frost. Retrieved from https://idiyas.com/inventor/jonathan-reid-frost

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 91.3

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 170(Granted Patents)


Location History:

  • Palaiseau, FR (1981 - 1982)
  • Cachan, FR (1984 - 1985)
  • Wissous, FR (1986 - 2008)

Company Filing History:

goldMedal20 out of 252 
 
Synthelabo
 patents
silverMedal2 out of 73 
 
Mitsubishi Pharma Corporation
 patents
bronzeMedal2 out of 390 
 
Sanofi-Aventis
 patents
4. 1 out of 152 
 
Sanofi-Synthelabo
 patents
where one patent can have more than one assignee

Years Active: 1981-2008

Loading Chart...
Areas of Expertise:
Pyrimidone Derivatives
Quinolinone Derivatives
Pyridinyl Compounds
Therapeutic Applications
Dioxane Derivatives
Piperidine Derivatives
Fluorinated Beta Keto-Esters
Benzoxazine Derivatives
Cerebrovascular Disease
Anti-Anoxic Compounds
Depression Treatment
Indole Derivatives
23 patents (USPTO):Explore Patents
1. 7378413 - 2-amino-3-(alkyl)-pyrimidone derivatives (2008-05-27),
2. 7135569 - Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters (2006-11-14),
3. 6844335 - 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors (2005-01-18),
4. 5922739 - 5-Naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutical (1999-07-13),
5. 5663183 - N-(3-Aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide (1997-09-02),
6. 5620990 - Alpha-(4-chlorophenyl)-4-[(4-fluorphenyl)-methyl]piperidine-1-ethanol (1997-04-15),
7. 5550162 - N-(-3-aminopropyl)-N-phenyl-5,6,7,8-tetrahydro-naphthalene-2-carboxamide (1996-08-27),
8. 5550125 - 3-(2-aminomethyl)-4-[3-trifluoromethyl)benzoyl]-3-4 (1996-08-27),
9. 5447928 - Benzoxazine derivatives and their application in therapy (1995-09-05),
10. 5212181 - 1-(3,4-dihydro-2-oxo-1H-quinolin-6-yl)-2-[4-(2-phenylethyl)piperidin-1-yl]e (1993-05-18),
11. 5034401 - Derivatives of (1-hydroxy-2-piperidylalkyl-indol-2-ones, 2-quinolinones, (1991-07-23),
12. 5023266 - Method of treatment of psychotic disorders (1991-06-11),
13. 4983607 - Quinolinone derivatives and their preparation in therapy (1991-01-08),
14. 4950670 - 6-phenyl-3-(piperazinyalalkyl)-2,4(1H,3H)-pyrimidinedione derivatives, (1990-08-21),
15. 4690931 - Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives (1987-09-01),

Title: The Contributions of Jonathan Reid Frost to Pharmaceutical Innovations

Introduction: Jonathan Reid Frost is a notable inventor based in Wissous, France, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 23 patents, he has made strides in developing innovative solutions for complex medical challenges, particularly neurodegenerative diseases.

Latest Patents: Among his recent innovations, Frost has patented two notable inventions: the first pertains to 2-amino-3-(alkyl)-pyrimidone derivatives. This patent outlines a pyrimidone derivative represented by a specific formula or a salt thereof. It forms the basis of a medicament that includes this derivative or its salt as an active ingredient, aimed at preventive and therapeutic treatment of neurodegenerative diseases linked to the abnormal activity of GSK3β, such as Alzheimer’s disease. His second patent details a process for preparing pyridinyl and pyrimidinyl mono-fluorinated beta keto esters. This process involves synthesizing these esters, which are of considerable interest in pharmaceutical applications.

Career Highlights: Throughout his career, Jonathan Reid Frost has made significant contributions while working with leading pharmaceutical companies, including Synthelabo and Mitsubishi Pharma Corporation. His work in these organizations has allowed him to play a crucial role in the advancement of innovative therapeutic solutions.

Collaborations: In his endeavors, Frost collaborated with several esteemed colleagues such as Patrick Andre Lardenois and Alexander E Wick. Their combined expertise has fostered an environment of creativity and innovation, leading to breakthroughs in drug development.

Conclusion: Jonathan Reid Frost’s dedication to advancing pharmaceutical research and development is demonstrated through his extensive patent portfolio and collaborative efforts. His work not only contributes to expanding scientific knowledge but also promises improved treatment options for patients suffering from challenging conditions like neurodegenerative diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…